SCHEMBL190886

SCHEMBL190886

Clc1cccc(Sc2ccnc(Cl)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 3/20 0.53
HPGD P15428 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
GRM5 P41594 2/20 0.49
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
FBP1 P09467 1/20 0.45
POLB P06746 1/20 0.44
RHEB Q15382 1/20 0.41
EGFR P00533 1/20 0.40
LCK P06239 1/20 0.40
DHFR P00374 1/20 0.40
MAPT P10636 3/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PPP1CA P62136 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191141 0.85 TRPA1 (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL2282611 0.82 POLB (0.56) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL29543630 0.82 POLB (0.56) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL30688805 0.82 POLB (0.56) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL191183 0.81 L3MBTL1 (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL10596007 0.80 POLB (0.55) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL190876 0.78 PTGIR (0.45) ALDH1A1KMT2AMEN1EGFRDHFR
SCHEMBL190493 0.78 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL10708413 0.78 POLB (0.62) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL31749709 0.77 GRM5 (0.35) ALDH1A1KDM4EHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
CN-101437512-A Glucokinase activators ARRAY BIOPHARMA INC (US) 2009-05-20 CN disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 ALDH1A1 1869/4885KDM4E 2939/4885HPGD 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.